Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...
Hosted on MSN4h
Study Finds Exenatide Not Beneficial for Parkinson DiseaseThe glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, ...
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.
The nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) study was conducted to examine the effects of semaglutide ...
HealthDay on MSN3d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of TreatmentThe absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.
Molina Healthcare CEO Joseph Zubretsky downplayed GOP proposals to slash spending on Medicaid, which accounts for about 80% ...
Sen. Dick Durbin (D-Ill.) and Sen. Dr. Roger Marshall (R-Kan.) sent a letter to Food and Drug Administration acting ...
Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback